epidemic, very few of the available HIV-prevention interventions for African American populations have been designed specifically for MSM. In fact, until very recently none of CDC’s evidence-based, HIV-prevention interventions had been specifically tested for efficacy in reducing HIV transmission among MSM of color. Given the conspicuous absence of (1) evidence-based HIV interventions and (2) outcome evaluations of existing AAMSM interventions, our collaborative team intends to address a glaring research gap by implementing a best-practices model of comprehensive program evaluation.

The purpose of this project is to test in a real world setting the efficacy of an HIV transmission prevention intervention for reducing sexual risk among African American men who have sex with men in Los Angeles County. The intervention is a 3-session, group-level intervention that will provide participants with the information, motivation, and skills necessary to reduce their risk of transmitting or acquiring HIV. The intervention will be evaluated using baseline, 3 month and 6 month follow up questionnaires. This project will also conduct in-depth qualitative interviews with 36 men in order to assess the experiences with the intervention, elicit recommendations for improving the intervention, and to better understand the factors that put young African American MSM at risk for HIV.

CDC is requesting approval for a 3-year clearance for data collection. The data collection system involves screenings, limited locator information, contact information, baseline questionnaire, client satisfaction surveys, 3-month follow-up questionnaire, 6-month follow-up questionnaire, and case study interviews. An estimated 700 men will be screened for eligibility in order to enroll 528 men. The baseline and follow up questionnaires contain questions about participants’ socio-demographic information, health and healthcare, sexual activity, substance use, and other psychosocial issues. The duration of each baseline, 3-month, and 6-month questionnaires are estimated to be 60 minutes; the Success Case Study interviews 90 minutes; Outreach Recruitment Assessment 5 minutes; limited locator information form 5 minutes; participant contact information form 10 minutes; each client satisfaction survey 5 minutes.

There are no costs to the respondents other than their time. The total estimated annual burden hours are 1662.

### ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondent</th>
<th>Form name</th>
<th>Number of respondents</th>
<th>Number responses per respondent</th>
<th>Average burden per respondent (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prospective Participant</td>
<td>Outreach Recruitment Assessment ( screener )</td>
<td>700</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td>Prospective Participant</td>
<td>Limited Locator Information</td>
<td>700</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td>Enrolled Participant</td>
<td>Participant Contact Information Form</td>
<td>528</td>
<td>1</td>
<td>10/60</td>
</tr>
<tr>
<td>Enrolled Participant</td>
<td>Baseline Questionnaire</td>
<td>528</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Enrolled Participant</td>
<td>Client Satisfaction Survey</td>
<td>224</td>
<td>3</td>
<td>5/60</td>
</tr>
<tr>
<td>Enrolled Participant</td>
<td>3 month follow up Questionnaire</td>
<td>420</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Enrolled Participant</td>
<td>6 month follow up Questionnaire</td>
<td>400</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Enrolled Participant</td>
<td>Success Case Study Interview</td>
<td>36</td>
<td>1</td>
<td>1.5</td>
</tr>
</tbody>
</table>

Dated: October 7, 2011.

Daniel Holcomb,
Reports Clearance Officer, Centers for Disease Control and Prevention.

[FR Doc. 2011–26603 Filed 10–13–11; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, Office of Infectious Diseases (BSC, OID)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

**Time and Date:** 8 a.m.–4:30 p.m., November 9, 2011.

**Place:** CDC, Global Communications Center, 1600 Clifton Road, NE., Building 19, Auditorium B3, Atlanta, Georgia 30333.

**Status:** Open to the public, limited only by the space available.

**Purpose:** The BSC, OID, provides advice and guidance to the Secretary, Department of Health and Human Services; the Director, CDC; the Director, OID; and the Directors of the National Center for Immunization and Respiratory Diseases, the National Center for Emerging and Zoonotic Infectious Diseases, and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, in the following areas: strategies, goals, and priorities for programs; research within the national centers; and overall strategic direction and focus of OID and the national centers.

**Matters To Be Discussed:** The meeting will include brief updates from OID and the three infectious disease national centers, a report from the OID/BSC Food Safety Modernization Act working group, and presentation of the recently released strategic framework for CDC’s infectious disease programs. The main topic of the meeting will include a focused discussion, with breakout groups, on the changing roles and responsibilities for public health infectious disease laboratories and the challenges and opportunities related to new diagnostics, other technologic advances, and a changing economic environment.

Agenda items are subject to change as priorities dictate.

**Contact Person for More Information:** Robin Moseley, M.A.T., Designated Federal Officer, OID, CDC, 1600 Clifton Road, NE., Mailstop D10, Atlanta, Georgia 30333, Telephone: (404) 639–4461.

The Director, Management Analysis and Services Office has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry.

Dated: October 6, 2011.

Catherine Ramadei,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011–26589 Filed 10–13–11; 8:45 am]

BILLING CODE 4163–18–P